Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

The TOPICAL trial

2010 ASCO Annual Meeting

Published: 3 Aug 2010

Views: 8663

Rating:

Save

Dr Siow Ming Lee, University College London, UK

Dr Lee speaks about the TOPICAL trial, a randomised phase III trial of erlotinib in chemotherapy-naive patients with advanced non-small cell lung cancer who are unsuitable for first-line chemotherapy. Erlotinib was shown to significantly increase progression free survival in female patients but not in males.

Related Videos

ESMO and WCLC: Latest developments in EGFR mutated NSCLC

Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale...

ESMO and WCLC: Latest developments in EGFR mutated NSCLC ( Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini )

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC

Dr Marina Garassino - University of Chicago, Chicago, USA

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )

Amivantamab-lazertinib continue to show benefit as a first-line standard-of...

Dr Marina Garassino - University of Chicago, Chicago, USA

Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )

ESMO 2024: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2024: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

Immunotherapy resistance pathways investigated to tailor combination NSCLC...

Prof Pascale Tomasini - Aix-Marseille University, Marseille, France

Immunotherapy resistance pathways investigated to tailor combination NSCLC therapy ( Prof Pascale Tomasini - Aix-Marseille University, Marseille, France )

Mutational-based treatment approach may significantly improve outcomes in...

Dr Andrea Botticelli - Sapienza Università di Roma, Rome, Italy

Mutational-based treatment approach may significantly improve outcomes in pretreated patients with metastatic solid tumours ( Dr Andrea Botticelli - Sapienza Università di Roma, Rome, Italy )

ESMO 2024: Latest in EGFR mutated NSCLC

Prof Ignacio Gil-Bazo, Dr Mariana Brandão, Prof Benjamin Besse and Prof...

ESMO 2024: Latest in EGFR mutated NSCLC ( Prof Ignacio Gil-Bazo, Dr Mariana Brandão, Prof Benjamin Besse and Prof Enriqueta Felip )

Biomarkers, predictive and prognostic factors of resistance to immunotherapy

Dr Ignacio Gil-Bazo - Fundación Instituto Valenciano de Oncología (FIVO)...

Biomarkers, predictive and prognostic factors of resistance to immunotherapy ( Dr Ignacio Gil-Bazo - Fundación Instituto Valenciano de Oncología (FIVO)/Clínica Universidad de Navarra, Spain )

Uncommon genetic aberrations NTRK, RET, NRG

Dr Luis E. Raez - Memorial Cancer Institute, Miami, USA

Uncommon genetic aberrations NTRK, RET, NRG ( Dr Luis E. Raez - Memorial Cancer Institute, Miami, USA )

More from ecancer